ClinicalTrials.gg
CompletedNCT03850483Updated Jun 29, 2022Results posted

Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis

A Phase 2 interventional study of PF-06700841 and Vehicle (Placebo) in Psoriasis, sponsored by Pfizer. Completed at 79 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-06-29.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
344
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies in Psoriasis by Pfizer — none open to participants now, none under way, none of them phase 3. Psoriasis · Pfizer.

Enrollment
12th of 42
344 · median 120
Started
2019
with 1 other
Phase 2
13 of 57
none open now
Registered
53rd of 57
by date

Among the 57 studies in Psoriasis by Pfizer, this one is the 12th largest by enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2019, is one of 13 in phase 2, and was the 53rd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

None of the 57 studies in Psoriasis by Pfizer is open now. The open studies under Psoriasis, anywhere →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 57 studies in Psoriasis by Pfizer as a file.
02

Study summary

This is a Phase 2b, randomized, double blind, vehicle controlled, parallel group, multicenter study in participants with mild to moderate plaque psoriasis. The duration of study participation will be approximately 22 weeks, including up to a 6 week screening period, 12 week treatment period, and approximately 4 week follow up period. Approximately 280 participants are planned to be randomized into the study.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • psoriasis
  • topical
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • plaque psoriasis for 6 months
  • PGA score mild or moderate
  • body surface area (BSA) 2-15%

Exclusion criteria

Exclusion Criteria:

  • other skin conditions that would interfere with the evaluation of psoriasis
  • history of herpes zoster or simplex
  • Infected with Mycobacterium tuberculosis
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
344 participants (actual)

Study arms

  • Placebo comparator
    Vehicle cream QD

    Vehicle cream applied once daily (QD)

    Drug: Vehicle (Placebo)

  • Experimental
    PF-06700841 0.1% cream QD

    PF-06700841 0.1% cream applied once daily (QD)

    Drug: PF-06700841

  • Experimental
    PF-06700841 0.3% cream QD

    PF-06700841 0.3% cream applied once daily (QD)

    Drug: PF-06700841

  • Experimental
    PF-06700841 1% cream QD

    PF-06700841 1% cream applied once daily (QD)

    Drug: PF-06700841

  • Experimental
    PF-06700841 3% cream QD

    PF-06700841 3% cream applied once daily (QD)

    Drug: PF-06700841

  • Experimental
    PF-06700841 0.3% cream BID

    PF-06700841 0.3% cream applied twice daily (BID)

    Drug: PF-06700841

  • Experimental
    PF-06700841 1% cream BID

    PF-06700841 1% cream applied twice daily (BID)

    Drug: PF-06700841

  • Placebo comparator
    Vehicle cream BID

    Vehicle cream applied twice daily (BID)

    Drug: Vehicle (Placebo)

  • Experimental
    PF-06700841 3% cream BID

    PF-06700841 3% cream applied twice daily (BID)

    Drug: PF-06700841

Interventions

  • PF-06700841 topical cream

  • DrugVehicle (Placebo)

    Vehicle topical cream

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12

    The Psoriasis Area and Severity Index (PASI) score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected body surface area (BSA) from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Percentage of Participants With Physician Global Assessment (PGA) Score Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12

    PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category. Scale for PGA: 0= clear, 1= almost clear, 2= mild, 3= moderate and 4= severe. Higher scores indicate more severity.

    Time frame: Baseline, Week 12

  2. Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16

    The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.

    Time frame: Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14, and 16

  3. Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12

    The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.

    Time frame: Baseline, Week 1, 2, 4, 6, 8, 10 and 12

  4. Change From Baseline in PASI Scores at Week 14 and 16

    The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.

    Time frame: Baseline, Week 14 and 16

  5. Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12

    The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.

    Time frame: Baseline, Week 1, 2, 4, 6, 8, 10 and 12

  6. Percent Change From Baseline in PASI Scores at Week 14 and 16

    The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.

    Time frame: Baseline, Week 14 and 16

  7. Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12

    Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch.

    Time frame: Baseline, Week 1, 2, 4, 6, 8, 10 and 12

  8. Absolute PP-NRS Score at Week 14 and 16

    Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch.

    Time frame: Week 14 and 16

  9. Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12

    Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch.

    Time frame: Baseline, Week 1, 2, 4, 6, 8, 10 and 12

  10. Change From Baseline in PP-NRS Score at Week 14 and 16

    Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch.

    Time frame: Baseline, Week 14 and 16

  11. Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2

    PSI was a self-administered 8-item questionnaire that measured the severity of psoriasis symptoms over the past 24 hours and the past 7 days. PSI included following 8 items: itch, pain, burning, stinging, cracking, scaling, flaking, and redness. Each item was rated on a scale from 0 to 4, where 0= not at all severe, 1= mild, 2= moderate, 3= severe and 4= very severe. Scores from all items were summed to give PSI score range from 0 (no severity) to 32 (maximum severity), higher PSI score indicated greater severity.

    Time frame: Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET (Prior to Week 12), ET Follow-up Visit 1 (2 weeks post ET) and 2 (4 weeks post ET)

  12. Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2

    PSI was a self-administered 8-item questionnaire that measured the severity of psoriasis symptoms over the past 24 hours and the past 7 days. PSI included following 8 items: itch, pain, burning, stinging, cracking, scaling, flaking, and redness. Each item was rated on a scale from 0 to 4, where 0= not at all severe, 1= mild, 2= moderate, 3= severe and 4= very severe. Scores from all items were summed to give PSI score range from 0 (no severity) to 32 (maximum severity), higher PSI score indicated greater severity.

    Time frame: Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET (Prior to Week 12), ET Follow-up Visit 1 (2 weeks post ET) and 2 (4 weeks post ET)

  13. Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16

    PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category. Scale for PGA: 0= clear, 1= almost clear, 2= mild, 3= moderate and 4= severe. Higher scores indicate more severity.

    Time frame: Baseline, Week 1, 2, 4, 6, 8, 10, 14, and 16

  14. Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16

    PSI was a self-administered 8-item questionnaire that measured the severity of psoriasis symptoms over the past 24 hours and the past 7 days. PSI included following 8 items: itch, pain, burning, stinging, cracking, scaling, flaking, and redness. Each item was rated on a scale from 0 to 4, where 0= not at all severe, 1= mild, 2= moderate, 3= severe and 4= very severe. Scores from all items were summed to give PSI score range from 0 (no severity) to 32 (maximum severity), higher PSI score indicated greater severity.

    Time frame: Week 1, 2, 4, 6, 8, 10, 12, 14, and 16

  15. Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and all non-SAEs. Treatment emergent AEs (TEAEs) were events that occurred between first dose of study drug and up to 4 weeks after last dose that were absent before treatment or that worsened relative to pretreatment state. A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug. Relatedness to study drug was assessed by the investigator.

    Time frame: Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks)

  16. Number of Participants With TEAEs by Severity

    An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. AE was assessed according to severity; mild (not causing any significant problem, dose adjustment not required), moderate (caused problem that does not interfere significantly with usual activities or the clinical status, dose adjustment needed due to adverse event) and severe (caused problem that interfered significantly with usual activities or the clinical status, study drug stopped due to adverse event).

    Time frame: Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks)

  17. Number of Participants Who Discontinued From Study Due to Adverse Events

    An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.

    Time frame: Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks)

  18. Number of Participants With Laboratory Abnormalities Meeting Specified Criteria

    Bilirubin: greater than (\>) 1.5\* upper limit normal (ULN); aspartate aminotransferase, alanine aminotransferase: \>2.5\*ULN; creatinine, cystatin C: \>1.3\*ULN; creatine kinase: \>2.0\*ULN; glomerular filtration rate (GFR) CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) Equat: less than (\<) 60 milliliter (mL)/minute (min)/1.73 meter(m)\^2, greater than or equal to (\>=) 30% decrease from baseline; GFR: \<60 mL/min/1.73m\^2.

    Time frame: Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks)

  19. Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data

    Following were ECG criteria used for categorical summary:1) PR interval: percentage change \>=25/50%, QRS interval: value \>140 msec, and QT interval corrected using the Fridericia's formula (QTcF): 450 msec \< value less than equal to (\<=) 480 and 30 \< change \<=60.

    Time frame: Post-baseline to Week 6, Post-baseline to Week 12

  20. Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data

    Following were the vital signs criteria: 1) Pulse rate: value \<40 beats per min (bpm), value \>120 bpm; 2) Sitting diastolic blood pressure (DBP): value \<50 mmHg; change \>=20 mmHg increase; change \>=20 mmHg decrease; 3) Sitting systolic blood pressure (SBP): value \<90 mmHg, change \>=30 mmHg increase, change \>=30 mmHg decrease; 4) Supine DBP: value \<50 mmHg, change \>=20 mmHg increase, change \>=20 mmHg decrease; 5) Supine SBP: value \<90 mmHg, change \>=30 mmHg increase, change \>=30 mmHg decrease.

    Time frame: Post-baseline to Week 12

  21. Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16

    At the site of study drug application, skin tolerability was assessed for non-lesional skin surrounding the plaques on a scale from 0 to 4. Grade 0= none (no evidence of local intolerance), Grade 1= mild (minimal erythema and/or edema, slight glazed appearance), Grade 2= moderate (definite erythema and/or oedema with peeling and/or cracking but needs no adaptation of posology), Grade 3= severe, reported as AE (erythema, oedema glazing with fissures, few vesicles or papules: consider removing topical agent \[if still in place\]), Grade 4= very severe, reported as AE (strong reaction spreading beyond the treated area, bullous reaction, erosions: removal of topical agent \[if still in place\]).

    Time frame: Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16

07

Results

Posted Jun 29, 2022

Participant flow

Treatment for Stage 1
Participant flow — Treatment for Stage 1
MilestoneStage 1: Vehicle Once Daily (QD)Stage 1: PF-06700841 0.1% QDStage 1: PF-06700841 0.3% QDStage 1: PF-06700841 1.0% QDStage 1: PF-06700841 3.0% QDStage 1: Vehicle Twice Daily (BID)Stage 1: PF-06700841 0.3% BIDStage 1: PF-06700841 1.0% BIDStage 2: Vehicle BIDStage 2: PF-06700841 3.0% BID
Started373737363738363600
Treated373737363737363600
Completed292926302827253000
Not completed8811691111600
Withdrew: Adverse event1130202200
Withdrew: Withdrawal by subject4422212300
Withdrew: Protocol violation1000001000
Withdrew: Physician decision0000010000
Withdrew: Other0000210000
Withdrew: Non-compliance with study drug0010000000
Withdrew: No longer met eligibility criteria0000010000
Withdrew: Lost to follow-up0111012000
Withdrew: Lack of efficacy1223243100
Withdrew: Death0000010000
Withdrew: Refused further treatment1020101000
Withdrew: Randomized but not treated0000010000
Follow-up for Stage 1
Participant flow — Follow-up for Stage 1
MilestoneStage 1: Vehicle Once Daily (QD)Stage 1: PF-06700841 0.1% QDStage 1: PF-06700841 0.3% QDStage 1: PF-06700841 1.0% QDStage 1: PF-06700841 3.0% QDStage 1: Vehicle Twice Daily (BID)Stage 1: PF-06700841 0.3% BIDStage 1: PF-06700841 1.0% BIDStage 2: Vehicle BIDStage 2: PF-06700841 3.0% BID
Started373737363737363600
Completed373435343433343300
Not completed0322342300
Withdrew: Withdrawal by subject0000001200
Withdrew: Physician decision0000101000
Withdrew: Lack of efficacy0010000100
Withdrew: Adverse event0010010000
Withdrew: Refused further study procedures0100220000
Withdrew: Other0202010000
Treatment for Stage 2
Participant flow — Treatment for Stage 2
MilestoneStage 1: Vehicle Once Daily (QD)Stage 1: PF-06700841 0.1% QDStage 1: PF-06700841 0.3% QDStage 1: PF-06700841 1.0% QDStage 1: PF-06700841 3.0% QDStage 1: Vehicle Twice Daily (BID)Stage 1: PF-06700841 0.3% BIDStage 1: PF-06700841 1.0% BIDStage 2: Vehicle BIDStage 2: PF-06700841 3.0% BID
Started000000001238
Completed00000000727
Not completed00000000511
Withdrew: Adverse event0000000001
Withdrew: Lack of efficacy0000000010
Withdrew: Lost to follow-up0000000003
Withdrew: Physician decision0000000001
Withdrew: Protocol violation0000000010
Withdrew: Withdrawal by subject0000000025
Withdrew: No longer meets eligibility criteria0000000001
Withdrew: Refused further treatment0000000010
Follow-up For Stage 2
Participant flow — Follow-up For Stage 2
MilestoneStage 1: Vehicle Once Daily (QD)Stage 1: PF-06700841 0.1% QDStage 1: PF-06700841 0.3% QDStage 1: PF-06700841 1.0% QDStage 1: PF-06700841 3.0% QDStage 1: Vehicle Twice Daily (BID)Stage 1: PF-06700841 0.3% BIDStage 1: PF-06700841 1.0% BIDStage 2: Vehicle BIDStage 2: PF-06700841 3.0% BID
Started000000001238
Completed000000001236
Not completed0000000002
Withdrew: Lost to follow-up0000000001
Withdrew: Other0000000001

Outcome measures

PrimaryChange From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12

The Psoriasis Area and Severity Index (PASI) score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected body surface area (BSA) from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Unit on a scale
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12
Unit on a scaleVehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BID
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12-1.6 ± 0.46-2.2 ± 0.46-1.4 ± 0.46-2.2 ± 0.46-2.4 ± 0.45-2.2 ± 0.42-2.5 ± 0.53-3.0 ± 0.51-2.8 ± 0.48
Statistical analysis
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · ANCOVA · p = 0.1641 (Multiplicity adjustment comparing 6 different treatment arms was performed only for the primary endpoint using Hochberg step-up procedure to maintain overall familywise error rate at 5% level.) · Least square (ls) mean difference: -0.6 · 90% CI -1.71 to 0.43
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · ANCOVA · p = 0.6100 (Multiplicity adjustment comparing 6 different treatment arms was performed only for the primary endpoint using Hochberg step-up procedure to maintain overall familywise error rate at 5% level.) · Ls mean difference: 0.2 · 90% CI -0.89 to 1.26
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · ANCOVA · p = 0.1686 (Multiplicity adjustment comparing 6 different treatment arms was performed only for the primary endpoint using Hochberg step-up procedure to maintain overall familywise error rate at 5% level.) · Ls mean difference: -0.6 · 90% CI -1.70 to 0.45
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · ANCOVA · p = 0.1051 (Multiplicity adjustment comparing 6 different treatment arms was performed only for the primary endpoint using Hochberg step-up procedure to maintain overall familywise error rate at 5% level.) · Ls mean difference: -0.8 · 90% CI -1.87 to 0.25
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · ANCOVA · p = 0.3583 (Multiplicity adjustment comparing 6 different treatment arms was performed only for the primary endpoint using Hochberg step-up procedure to maintain overall familywise error rate at 5% level.) · Ls mean difference: -0.2 · 90% CI -1.37 to 0.88
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · ANCOVA · p = 0.1131 (Multiplicity adjustment comparing 6 different treatment arms was performed only for the primary endpoint using Hochberg step-up procedure to maintain overall familywise error rate at 5% level.) · Ls mean difference: -0.8 · 90% CI -1.88 to 0.29
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · ANCOVA · p = 0.1812 (Multiplicity adjustment comparing 6 different treatment arms was performed only for the primary endpoint using Hochberg step-up procedure to maintain overall familywise error rate at 5% level.) · Ls mean difference: -0.6 · 90% CI -1.64 to 0.47
SecondaryPercentage of Participants With Physician Global Assessment (PGA) Score Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12

PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category. Scale for PGA: 0= clear, 1= almost clear, 2= mild, 3= moderate and 4= severe. Higher scores indicate more severity.

Time frame:
Baseline, Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Physician Global Assessment (PGA) Score Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12
Percentage of participantsVehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BID
Percentage of Participants With Physician Global Assessment (PGA) Score Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 126.9 (1.8 to 20.0)10.3 (3.9 to 22.9)15.4 (6.9 to 29.9)10.3 (3.9 to 22.9)21.4 (9.8 to 36.6)14.7 (7.3 to 26.9)20.8 (10.5 to 37.0)27.6 (14.5 to 42.5)17.9 (8.9 to 33.3)
Statistical analysis
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.3747 · Risk difference (rd): 3.4 · 90% CI -10.6 to 17.9
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.2430 · Risk difference (rd): 8.5 · 90% CI -6.6 to 25.9
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.3747 · Risk difference (rd): 3.4 · 90% CI -10.6 to 17.9
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.0665 · Risk difference (rd): 14.5 · 0.0665% CI -1.3 to 31.5
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.3423 · Risk difference (rd): 6.1 · 90% CI -12.1 to 25.5
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.1271 · Risk difference (rd): 12.9 · 90% CI -4.7 to 30.9
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.4010 · Risk difference (rd): 3.2 · 90% CI -13.2 to 21.1
SecondaryPercentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16

The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.

Time frame:
Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14, and 16
Reported as:
Number · Percentage of participants
Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16
Percentage of participantsVehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BID
Week 13.1 (0.3 to 13.1)3.0 (0.3 to 12.7)0 (0.0 to 8.0)0 (0.0 to 7.7)0 (0.0 to 7.7)0 (0.0 to 6.0)0 (0.0 to 8.5)2.9 (0.3 to 12.3)2.7 (0.3 to 11.2)
Week 23.1 (0.3 to 13.1)0 (0.0 to 7.5)0 (0.0 to 8.8)2.9 (0.3 to 11.9)0 (0.0 to 7.7)2.2 (0.2 to 9.2)0 (0.0 to 7.7)6.3 (1.7 to 18.0)5.7 (1.5 to 16.4)
week 43.1 (0.3 to 13.1)0 (0.0 to 8.5)3.6 (0.4 to 15.1)0 (0.0 to 8.0)0 (0.0 to 8.0)8.9 (3.9 to 18.0)6.7 (1.8 to 19.3)3.0 (0.3 to 12.7)12.1 (5.4 to 25.1)
Week 63.2 (0.3 to 13.5)0 (0.0 to 8.8)7.4 (2.0 to 20.4)6.5 (1.7 to 18.7)10.3 (3.9 to 22.9)13.9 (6.9 to 25.4)10.7 (4.0 to 23.8)10.7 (4.0 to 23.8)10.3 (3.9 to 22.9)
Week 86.7 (1.8 to 19.3)6.7 (1.8 to 19.3)7.4 (2.0 to 20.4)6.5 (1.7 to 18.7)14.3 (6.4 to 28.4)13.9 (6.9 to 25.4)16.0 (7.2 to 30.7)13.8 (6.2 to 27.9)14.3 (6.4 to 28.4)
Week 1010.3 (3.9 to 22.9)3.3 (0.4 to 14.0)8.0 (2.1 to 21.4)17.2 (8.6 to 32.0)14.3 (6.4 to 28.4)18.2 (8.2 to 31.3)20.8 (10.5 to 37.0)10.7 (4.0 to 23.8)15.4 (6.9 to 29.9)
Week 1210.3 (3.9 to 22.9)10.3 (3.9 to 22.9)7.7 (2.1 to 20.9)20.7 (9.4 to 35.2)17.9 (8.9 to 33.3)20.6 (11.3 to 34.9)12.5 (4.7 to 28.2)24.1 (13.4 to 38.5)17.9 (8.9 to 33.3)
Week 143.4 (0.4 to 14.5)7.7 (2.1 to 20.9)8.7 (2.3 to 22.8)21.4 (9.8 to 36.6)14.3 (6.4 to 28.4)10.3 (3.9 to 22.9)13.0 (4.9 to 29.6)20.0 (10.1 to 36.2)14.8 (6.6 to 29.1)
Week 163.4 (0.4 to 14.5)11.1 (4.2 to 24.8)17.4 (7.8 to 33.5)25.0 (13.9 to 40.0)15.4 (6.9 to 29.9)16.1 (8.1 to 29.7)13.0 (4.9 to 29.6)12.5 (4.7 to 28.2)15.4 (6.9 to 29.9)
Statistical analysis
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.4225 · Risk difference (rd): -0.1 · 90% CI -11.2 to 10.4
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.7483 · Risk difference (rd): -3.1 · 90% CI -14.0 to 5.0
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.7539 · Risk difference (rd): -3.1 · 90% CI -14.0 to 4.8
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.7539 · Risk difference (rd): -3.1 · 90% CI -14.0 to 4.8
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.5000 · Risk difference (rd): 0.0 · 90% CI -6.4 to 8.9
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.2125 · Risk difference (rd): 2.9 · 90% CI -3.4 to 13.2
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.2267 · Risk difference (rd): 2.7 · 90% CI -3.5 to 12.2
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.7592 · Risk difference (rd): -3.1 · 90% CI -14.0 to 4.6
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.7299 · Risk difference (rd): -3.1 · 90% CI -14.0 to 5.5
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.4463 · Risk difference (rd): -0.3 · 90% CI -11.3 to 9.4
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.7539 · Risk difference (rd): -3.1 · 90% CI -14.0 to 4.8
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.7009 · Risk difference (rd): -2.2 · 90% CI -10.1 to 5.9
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.2507 · Risk difference (rd): 4.0 · 90% CI -4.5 to 15.6
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.2993 · Risk difference (rd): 3.5 · 90% CI -4.8 to 14.3
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.7363 · Risk difference (rd): -3.1 · 90% CI -14.0 to 5.5
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.5369 · Risk difference (rd): 0.4 · 90% CI -10.5 to 12.3
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.7483 · Risk difference (rd): -3.1 · 90% CI -14.0 to 5.0
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.7483 · Risk difference (rd): -3.1 · 90% CI -14.0 to 5.0
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.5990 · Risk difference (rd): -2.2 · 90% CI -13.7 to 11.6
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.7926 · Risk difference (rd): -5.9 · 90% CI -16.4 to 4.9
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.3402 · Risk difference (rd): 3.2 · 90% CI -9.0 to 17.6
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.7364 · Risk difference (rd): -3.2 · 90% CI -14.4 to 5.7
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.3009 · Risk difference (rd): 4.2 · 90% CI -7.4 to 17.7
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.3400 · Risk difference (rd): 3.2 · 90% CI -8.1 to 15.9
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.1631 · Risk difference (rd): 7.1 · 90% CI -4.8 to 21.1
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.6214 · Risk difference (rd): -3.2 · 90% CI -17.8 to 13.0
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.6214 · Risk difference (rd): -3.2 · 90% CI -17.8 to 13.0
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.6413 · Risk difference (rd): -3.5 · 90% CI -17.9 to 11.7
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.5000 · Risk difference (rd): 0.0 · 90% CI -13.1 to 13.1
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.5134 · Risk difference (rd): 0.7 · 90% CI -12.6 to 15.2
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.4468 · Risk difference (rd): -0.2 · 90% CI -13.4 to 12.5
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.2778 · Risk difference (rd): 7.6 · 90% CI -6.8 to 23.9
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.4571 · Risk difference (rd): 2.1 · 90% CI -14.5 to 21.0
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.4741 · Risk difference (rd): -0.1 · 90% CI -15.3 to 16.7
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.5153 · Risk difference (rd): 0.4 · 90% CI -14.8 to 16.7
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.8287 · Risk difference (rd): -7.0 · 90% CI -21.1 to 5.3
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.5675 · Risk difference (rd): -2.3 · 90% CI -17.8 to 14.2
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.2648 · Risk difference (rd): 6.9 · 90% CI -9.8 to 23.2
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.3792 · Risk difference (rd): 3.9 · 90% CI -11.8 to 20.8
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.4438 · Risk difference (rd): 2.7 · 90% CI -16.3 to 23.1
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.7014 · Risk difference (rd): -7.5 · 90% CI -23.3 to 9.4
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.5841 · Risk difference (rd): -2.8 · 90% CI -19.7 to 15.0
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.5000 · Risk difference (rd): 0.0 · 90% CI -15.3 to 15.3
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.5834 · Risk difference (rd): -2.7 · 90% CI -17.5 to 12.3
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.1534 · Risk difference (rd): 10.3 · 90% CI -6.4 to 27.2
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.2720 · Risk difference (rd): 7.5 · 90% CI -8.8 to 24.9
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.6815 · Risk difference (rd): -8.1 · 90% CI -25.1 to 10.4
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.3900 · Risk difference (rd): 3.5 · 90% CI -14.4 to 22.0
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.5865 · Risk difference (rd): -2.7 · 90% CI -20.0 to 15.9
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.3087 · Risk difference (rd): 4.2 · 90% CI -8.2 to 18.9
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.3137 · Risk difference (rd): 5.2 · 90% CI -8.2 to 20.9
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.0245 · Risk difference (rd): 18.0 · 90% CI 2.7 to 34.8
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.1119 · Risk difference (rd): 10.8 · 90% CI -3.0 to 26.0
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.4140 · Risk difference (rd): 2.7 · 90% CI -13.2 to 20.4
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.2356 · Risk difference (rd): 9.7 · 90% CI -7.2 to 28.5
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.3638 · Risk difference (rd): 4.5 · 90% CI -11.5 to 21.5
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.1613 · Risk difference (rd): 7.7 · 90% CI -5.2 to 22.9
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.0557 · Risk difference (rd): 13.9 · 90% CI -0.5 to 31.4
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.0114 · Risk difference (rd): 21.6 · 90% CI 5.6 to 38.3
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.0753 · Risk difference (rd): 11.9 · 90% CI -1.8 to 28.1
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.5635 · Risk difference (rd): -3.1 · 90% CI -20.1 to 15.2
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.6201 · Risk difference (rd): -3.6 · 90% CI -20.3 to 14.5
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.4792 · Risk difference (rd): -0.7 · 90% CI -17.6 to 17.0
SecondaryChange From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12

The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.

Time frame:
Baseline, Week 1, 2, 4, 6, 8, 10 and 12
Reported as:
Least squares mean · Unit on a scale
Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12
Unit on a scaleVehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BID
Change at Week 1-0.9 ± 0.22-0.7 ± 0.22-0.6 ± 0.22-0.9 ± 0.22-0.8 ± 0.22-0.5 ± 0.19-0.7 ± 0.23-0.7 ± 0.22-0.8 ± 0.22
Change at Week 2-1.4 ± 0.26-0.7 ± 0.26-0.9 ± 0.27-1.4 ± 0.26-1.3 ± 0.26-0.8 ± 0.25-1.4 ± 0.29-1.6 ± 0.29-1.7 ± 0.29
Change at Week 4-1.4 ± 0.31-1.2 ± 0.31-1.2 ± 0.33-1.4 ± 0.31-1.6 ± 0.31-1.0 ± 0.35-2.3 ± 0.42-1.7 ± 0.41-2.2 ± 0.41
Change at Week 6-1.5 ± 0.35-1.4 ± 0.35-1.2 ± 0.37-1.6 ± 0.35-2.4 ± 0.36-1.2 ± 0.37-2.5 ± 0.45-2.1 ± 0.44-2.1 ± 0.43
Change at Week 8-1.6 ± 0.39-1.9 ± 0.39-0.9 ± 0.41-2.1 ± 0.39-2.3 ± 0.40-1.3 ± 0.42-2.4 ± 0.50-2.3 ± 0.48-2.5 ± 0.48
Change at Week 10-1.6 ± 0.41-2.1 ± 0.40-1.6 ± 0.42-2.3 ± 0.40-2.4 ± 0.41-1.1 ± 0.46-2.4 ± 0.55-2.4 ± 0.53-2.4 ± 0.53
Change at Week 12-1.4 ± 0.49-2.1 ± 0.48-1.2 ± 0.51-2.2 ± 0.48-2.4 ± 0.49-0.9 ± 0.51-2.5 ± 0.62-2.5 ± 0.59-2.3 ± 0.59
Statistical analysis
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.8038 · Ls mean difference: 0.3 · 90% CI -0.25 to 0.79
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.8267 · Ls mean difference: 0.3 · 90% CI -0.22 to 0.81
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.6039 · Ls mean difference: 0.1 · 90% CI -0.43 to 0.60
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.6339 · Ls mean difference: 0.1 · 90% CI -0.41 to 0.62
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.2666 · Ls mean difference: -0.2 · 90% CI -0.68 to 0.31
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.2257 · Ls mean difference: -0.2 · 90% CI -0.70 to 0.26
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.1306 · Ls mean difference: -0.3 · 90% CI -0.81 to 0.15
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.9704 · Ls mean difference: 0.7 · 90% CI 0.09 to 1.31
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.8890 · Ls mean difference: 0.5 · 90% CI -0.16 to 1.09
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.4506 · Ls mean difference: 0.0 · 90% CI -0.66 to 0.57
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.5840 · Ls mean difference: 0.1 · 90% CI -0.53 to 0.69
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.0769 · Ls mean difference: -0.5 · 90% CI -1.17 to 0.08
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.0242 · Ls mean difference: -0.8 · 90% CI -1.39 to -0.13
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.0127 · Ls mean difference: -0.9 · 90% CI -1.49 to -0.23
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.6693 · Ls mean difference: 0.2 · 90% CI -0.54 to 0.93
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.6742 · Ls mean difference: 0.2 · 90% CI -0.55 to 0.96
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.4486 · Ls mean difference: -0.1 · 90% CI -0.79 to 0.67
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.3219 · Ls mean difference: -0.2 · 90% CI -0.93 to 0.53
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.0096 · Ls mean difference: -1.3 · 90% CI -2.21 to -0.39
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.0862 · Ls mean difference: -0.7 · 90% CI -1.64 to 0.15
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.0111 · Ls mean difference: -1.3 · 90% CI -2.15 to -0.36
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.6107 · Ls mean difference: 0.1 · 90% CI -0.68 to 0.97
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.7240 · Ls mean difference: 0.3 · 90% CI -0.54 to 1.15
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.4300 · Ls mean difference: -0.1 · 90% CI -0.91 to 0.74
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.0501 · Ls mean difference: -0.8 · 90% CI -1.66 to 0.00
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.0157 · Ls mean difference: -1.3 · 90% CI -2.23 to -0.30
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.0645 · Ls mean difference: -0.9 · 90% CI -1.83 to 0.07
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.0621 · Ls mean difference: -0.9 · 90% CI -1.84 to 0.06
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.2959 · Ls mean difference: -0.3 · 90% CI -1.21 to 0.62
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.9043 · Ls mean difference: 0.7 · 90% CI -0.19 to 1.69
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.2014 · Ls mean difference: -0.5 · 90% CI -1.38 to 0.45
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.0948 · Ls mean difference: -0.7 · 90% CI -1.66 to 0.19
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.0416 · Ls mean difference: -1.1 · 90% CI -2.21 to -0.06
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.0454 · Ls mean difference: -1.1 · 90% CI -2.14 to -0.03
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.0256 · Ls mean difference: -1.3 · 90% CI -2.31 to -0.20
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.2326 · Ls mean difference: -0.4 · 90% CI -1.36 to 0.53
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.5141 · Ls mean difference: 0.0 · 90% CI -0.95 to 0.99
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.1124 · Ls mean difference: -0.7 · 90% CI -1.64 to 0.25
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.0983 · Ls mean difference: -0.7 · 90% CI -1.70 to 0.21
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.0412 · Ls mean difference: -1.3 · 90% CI -2.46 to -0.07
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.0340 · Ls mean difference: -1.3 · 90% CI -2.47 to -0.13
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.0379 · Ls mean difference: -1.3 · 90% CI -2.44 to -0.09
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.1291 · Ls mean difference: -0.8 · 90% CI -1.91 to 0.36
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.5776 · Ls mean difference: 0.1 · 90% CI -1.03 to 1.30
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.1044 · Ls mean difference: -0.9 · 90% CI -2.00 to 0.27
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.0608 · Ls mean difference: -1.1 · 90% CI -2.23 to 0.07
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.0309 · Ls mean difference: -1.5 · 90% CI -2.84 to -0.18
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.0242 · Ls mean difference: -1.6 · 90% CI -2.85 to -0.26
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.0394 · Ls mean difference: -1.4 · 90% CI -2.69 to -0.09
SecondaryChange From Baseline in PASI Scores at Week 14 and 16

The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.

Time frame:
Baseline, Week 14 and 16
Reported as:
Mean · Unit on a scale
Change From Baseline in PASI Scores at Week 14 and 16
Unit on a scaleVehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BID
Baseline6.12 ± 2.8707.19 ± 3.3706.46 ± 2.9326.63 ± 3.4686.83 ± 3.1376.08 ± 2.5587.07 ± 3.5795.80 ± 2.7657.94 ± 4.071
Change at Week 14-0.83 ± 2.379-2.24 ± 2.945-0.72 ± 4.107-1.81 ± 3.228-1.87 ± 2.942-0.82 ± 3.581-1.04 ± 3.732-2.06 ± 3.343-1.19 ± 3.323
Change at Week 16-0.46 ± 2.603-2.06 ± 3.252-0.78 ± 4.223-2.10 ± 3.666-1.68 ± 3.255-0.67 ± 4.008-0.71 ± 3.455-1.75 ± 3.887-1.03 ± 3.351
SecondaryPercent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12

The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.

Time frame:
Baseline, Week 1, 2, 4, 6, 8, 10 and 12
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12
Percent changeVehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BID
Change at Week 1-15.5 ± 3.62-12.9 ± 3.57-8.2 ± 3.56-10.4 ± 3.49-13.0 ± 3.51-7.4 ± 3.10-9.0 ± 3.64-13.7 ± 3.58-13.5 ± 3.52
Change at Week 2-21.6 ± 4.25-12.4 ± 4.10-12.6 ± 4.34-17.9 ± 4.13-19.8 ± 4.14-11.7 ± 3.99-20.7 ± 4.60-23.3 ± 4.68-24.7 ± 4.58
Change at Week 4-24.1 ± 4.69-20.5 ± 4.65-15.6 ± 4.90-17.6 ± 4.59-25.1 ± 4.61-13.2 ± 5.69-33.9 ± 6.85-24.1 ± 6.66-29.2 ± 6.64
Change at Week 6-23.7 ± 5.88-20.3 ± 5.83-18.4 ± 6.18-21.8 ± 5.83-36.0 ± 5.92-17.8 ± 6.10-36.6 ± 7.31-31.2 ± 7.12-27.5 ± 7.08
Change at Week 8-25.3 ± 6.48-25.6 ± 6.44-14.3 ± 6.78-30.5 ± 6.41-35.9 ± 6.57-18.1 ± 6.70-35.2 ± 8.07-32.4 ± 7.76-34.3 ± 7.76
Change at Week 10-26.8 ± 6.42-27.6 ± 6.34-22.9 ± 6.73-35.3 ± 6.36-36.1 ± 6.48-12.5 ± 7.62-33.4 ± 9.12-35.1 ± 8.75-34.6 ± 8.77
Change at Week 12-20.0 ± 7.36-29.1 ± 7.30-18.5 ± 7.70-33.7 ± 7.30-39.0 ± 7.47-9.6 ± 8.61-34.1 ± 10.35-35.7 ± 9.84-33.7 ± 9.88
Statistical analysis
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.6917 · Ls mean difference: 2.6 · 90% CI -5.86 to 10.97
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.9241 · Ls mean difference: 7.3 · 90% CI -1.09 to 15.69
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.8443 · Ls mean difference: 5.1 · 90% CI -3.21 to 13.42
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.6911 · Ls mean difference: 2.5 · 90% CI -5.82 to 10.86
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.3676 · Ls mean difference: -1.6 · 90% CI -9.56 to 6.31
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.0915 · Ls mean difference: -6.3 · 90% CI -14.13 to 1.50
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.0970 · Ls mean difference: -6.2 · 90% CI -13.96 to 1.65
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.9389 · Ls mean difference: 9.2 · 90% CI -0.59 to 18.97
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.9295 · Ls mean difference: 9.0 · 90% CI -1.06 to 19.02
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.7308 · Ls mean difference: 3.7 · 90% CI -6.15 to 13.45
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.6199 · Ls mean difference: 1.8 · 90% CI -8.01 to 11.64
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.0699 · Ls mean difference: -9.0 · 90% CI -19.13 to 1.04
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.0300 · Ls mean difference: -11.6 · 90% CI -21.79 to -1.48
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.0168 · Ls mean difference: -13.1 · 90% CI -23.15 to -2.98
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.7083 · Ls mean difference: 3.6 · 90% CI -7.30 to 14.57
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.8955 · Ls mean difference: 8.5 · 90% CI -2.66 to 19.75
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.8386 · Ls mean difference: 6.5 · 90% CI -4.35 to 17.37
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.4371 · Ls mean difference: -1.0 · 90% CI -11.93 to 9.84
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.0108 · Ls mean difference: -20.7 · 90% CI -35.42 to -5.92
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.1066 · Ls mean difference: -10.9 · 90% CI -25.43 to 3.55
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.0344 · Ls mean difference: -16.0 · 90% CI -30.54 to -1.55
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.6594 · Ls mean difference: 3.4 · 90% CI -10.30 to 17.13
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.7307 · Ls mean difference: 5.3 · 90% CI -8.85 to 19.36
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.5914 · Ls mean difference: 1.9 · 90% CI -11.78 to 15.61
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.0709 · Ls mean difference: -12.3 · 90% CI -26.13 to 1.49
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.0253 · Ls mean difference: -18.8 · 90% CI -34.55 to -3.01
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.0780 · Ls mean difference: -13.4 · 90% CI -28.89 to 2.15
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.1516 · Ls mean difference: -9.7 · 90% CI -25.17 to 5.83
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.4861 · Ls mean difference: -0.3 · 90% CI -15.45 to 14.81
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.8795 · Ls mean difference: 11.0 · 90% CI -4.48 to 26.55
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.2867 · Ls mean difference: -5.1 · 90% CI -20.22 to 9.94
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.1267 · Ls mean difference: -10.6 · 90% CI -25.86 to 4.69
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.0526 · Ls mean difference: -17.1 · 90% CI -34.48 to 0.26
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.0827 · Ls mean difference: -14.3 · 90% CI -31.26 to 2.68
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.0592 · Ls mean difference: -16.1 · 90% CI -33.12 to 0.86
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.4657 · Ls mean difference: -0.8 · 90% CI -15.72 to 14.16
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.6612 · Ls mean difference: 3.9 · 90% CI -11.52 to 19.26
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.1749 · Ls mean difference: -8.5 · 90% CI -23.42 to 6.48
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.1548 · Ls mean difference: -9.3 · 90% CI -24.39 to 5.80
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.0400 · Ls mean difference: -21.0 · 90% CI -40.67 to -1.28
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.0267 · Ls mean difference: -22.6 · 90% CI -41.82 to -3.39
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.0295 · Ls mean difference: -22.2 · 90% CI -41.42 to -2.89
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.1903 · Ls mean difference: -9.1 · 90% CI -26.30 to 8.05
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.5530 · Ls mean difference: 1.4 · 90% CI -16.21 to 19.06
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.0933 · Ls mean difference: -13.8 · 90% CI -30.92 to 3.40
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.0360 · Ls mean difference: -19.0 · 90% CI -36.37 to -1.65
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.0354 · Ls mean difference: -24.5 · 90% CI -46.85 to -2.23
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.0239 · Ls mean difference: -26.1 · 90% CI -47.77 to -4.46
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.0342 · Ls mean difference: -24.1 · 90% CI -45.84 to -2.38
SecondaryPercent Change From Baseline in PASI Scores at Week 14 and 16

The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.

Time frame:
Baseline, Week 14 and 16
Reported as:
Mean · Percent change
Percent Change From Baseline in PASI Scores at Week 14 and 16
Percent changeVehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BID
Baseline6.12 ± 2.8707.19 ± 3.3706.46 ± 2.9326.63 ± 3.4686.83 ± 3.1376.08 ± 2.5587.07 ± 3.5795.80 ± 2.7657.94 ± 4.071
Change at Week 14-12.76 ± 49.660-25.94 ± 40.339-8.58 ± 59.407-23.14 ± 47.501-30.07 ± 40.222-5.74 ± 74.846-14.18 ± 58.599-27.56 ± 45.370-19.74 ± 49.727
Change at Week 16-4.72 ± 56.401-23.01 ± 44.766-9.00 ± 60.088-29.24 ± 52.608-27.17 ± 41.153-3.75 ± 83.415-9.99 ± 60.306-24.09 ± 48.685-21.12 ± 52.521
SecondaryAbsolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12

Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch.

Time frame:
Baseline, Week 1, 2, 4, 6, 8, 10 and 12
Reported as:
Least squares mean · Unit on a scale
Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12
Unit on a scaleVehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BID
Baseline4.6 ± 0.314.4 ± 0.304.5 ± 0.314.1 ± 0.334.5 ± 0.294.9 ± 0.284.8 ± 0.324.4 ± 0.325.4 ± 0.34
Week 14.1 ± 0.313.9 ± 0.303.6 ± 0.313.5 ± 0.333.6 ± 0.304.0 ± 0.283.8 ± 0.323.4 ± 0.323.7 ± 0.35
Week 23.6 ± 0.313.5 ± 0.313.3 ± 0.313.2 ± 0.333.5 ± 0.303.5 ± 0.283.6 ± 0.322.9 ± 0.323.4 ± 0.35
Week 43.5 ± 0.323.7 ± 0.323.2 ± 0.333.2 ± 0.343.2 ± 0.303.4 ± 0.293.0 ± 0.343.0 ± 0.343.4 ± 0.36
Week 63.5 ± 0.324.0 ± 0.323.5 ± 0.343.2 ± 0.342.9 ± 0.323.6 ± 0.312.8 ± 0.353.0 ± 0.352.9 ± 0.38
Week 83.1 ± 0.323.4 ± 0.323.2 ± 0.333.1 ± 0.342.8 ± 0.323.3 ± 0.322.7 ± 0.372.9 ± 0.352.7 ± 0.38
Week 103.3 ± 0.333.0 ± 0.333.0 ± 0.343.1 ± 0.352.3 ± 0.324.1 ± 0.332.8 ± 0.362.9 ± 0.353.6 ± 0.39
Week 123.4 ± 0.333.1 ± 0.333.1 ± 0.333.0 ± 0.352.6 ± 0.324.0 ± 0.322.7 ± 0.373.0 ± 0.353.2 ± 0.40
Statistical analysis
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.3279 · Ls mean difference: -0.2 · 90% CI -0.91 to 0.52
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.3566 · Ls mean difference: -0.2 · 90% CI -0.88 to 0.56
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.1165 · Ls mean difference: -0.5 · 90% CI -1.29 to 0.21
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.3633 · Ls mean difference: -0.1 · 90% CI -0.85 to 0.55
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.3766 · Ls mean difference: -0.1 · 90% CI -0.83 to 0.56
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.1179 · Ls mean difference: -0.5 · 90% CI -1.22 to 0.20
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.8647 · Ls mean difference: 0.5 · 90% CI -0.24 to 1.20
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.3294 · Ls mean difference: -0.2 · 90% CI -0.90 to 0.52
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.1231 · Ls mean difference: -0.5 · 90% CI -1.23 to 0.21
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.0878 · Ls mean difference: -0.6 · 90% CI -1.37 to 0.13
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.1225 · Ls mean difference: -0.5 · 90% CI -1.20 to 0.21
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.3663 · Ls mean difference: -0.1 · 90% CI -0.85 to 0.56
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.0929 · Ls mean difference: -0.6 · 90% CI -1.27 to 0.14
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.3111 · Ls mean difference: -0.2 · 90% CI -0.95 to 0.51
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.4745 · Ls mean difference: 0.0 · 90% CI -0.74 to 0.69
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.2409 · Ls mean difference: -0.3 · 90% CI -1.03 to 0.42
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.2018 · Ls mean difference: -0.4 · 90% CI -1.13 to 0.37
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.3925 · Ls mean difference: -0.1 · 90% CI -0.83 to 0.59
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.5348 · Ls mean difference: 0.0 · 90% CI -0.66 to 0.73
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.0739 · Ls mean difference: -0.6 · 90% CI -1.33 to 0.09
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.4014 · Ls mean difference: -0.1 · 90% CI -0.84 to 0.62
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.6588 · Ls mean difference: 0.2 · 90% CI -0.56 to 0.93
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.2997 · Ls mean difference: -0.2 · 90% CI -1.00 to 0.52
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.2518 · Ls mean difference: -0.3 · 90% CI -1.08 to 0.46
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.2634 · Ls mean difference: -0.3 · 90% CI -1.00 to 0.45
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.1999 · Ls mean difference: -0.4 · 90% CI -1.11 to 0.36
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.1847 · Ls mean difference: -0.4 · 90% CI -1.13 to 0.33
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.4569 · Ls mean difference: 0.0 · 90% CI -0.81 to 0.71
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.8536 · Ls mean difference: 0.5 · 90% CI -0.27 to 1.22
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.4812 · Ls mean difference: 0.0 · 90% CI -0.79 to 0.74
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.2276 · Ls mean difference: -0.4 · 90% CI -1.13 to 0.42
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.0895 · Ls mean difference: -0.6 · 90% CI -1.34 to 0.14
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.0411 · Ls mean difference: -0.8 · 90% CI -1.58 to -0.04
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.0928 · Ls mean difference: -0.6 · 90% CI -1.40 to 0.15
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.0799 · Ls mean difference: -0.7 · 90% CI -1.48 to 0.12
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.7872 · Ls mean difference: 0.4 · 90% CI -0.39 to 1.11
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.6294 · Ls mean difference: 0.2 · 90% CI -0.61 to 0.92
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.5174 · Ls mean difference: 0.0 · 90% CI -0.76 to 0.80
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.3136 · Ls mean difference: -0.2 · 90% CI -0.98 to 0.53
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.1020 · Ls mean difference: -0.6 · 90% CI -1.42 to 0.18
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.1923 · Ls mean difference: -0.4 · 90% CI -1.20 to 0.37
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.0997 · Ls mean difference: -0.6 · 90% CI -1.44 to 0.18
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.2497 · Ls mean difference: -0.3 · 90% CI -1.08 to 0.45
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.2568 · Ls mean difference: -0.3 · 90% CI -1.08 to 0.47
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.3730 · Ls mean difference: -0.2 · 90% CI -0.95 to 0.64
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.0137 · Ls mean difference: -1.0 · 90% CI -1.76 to -0.26
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.0055 · Ls mean difference: -1.3 · 90% CI -2.06 to -0.44
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.0069 · Ls mean difference: -1.2 · 90% CI -1.99 to -0.40
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.1648 · Ls mean difference: -0.5 · 90% CI -1.34 to 0.34
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.2931 · Ls mean difference: -0.3 · 90% CI -1.02 to 0.51
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.3047 · Ls mean difference: -0.2 · 90% CI -1.01 to 0.53
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.1924 · Ls mean difference: -0.4 · 90% CI -1.22 to 0.38
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.0465 · Ls mean difference: -0.8 · 90% CI -1.52 to -0.02
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.0048 · Ls mean difference: -1.3 · 90% CI -2.08 to -0.47
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.0186 · Ls mean difference: -1.0 · 90% CI -1.78 to -0.21
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.0675 · Ls mean difference: -0.8 · 90% CI -1.61 to 0.08
SecondaryAbsolute PP-NRS Score at Week 14 and 16

Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch.

Time frame:
Week 14 and 16
Reported as:
Mean · Unit on a scale
Absolute PP-NRS Score at Week 14 and 16
Unit on a scaleVehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BID
Week 145.2 ± 3.022.6 ± 2.522.8 ± 2.382.4 ± 2.393.2 ± 2.384.0 ± 2.773.5 ± 2.892.8 ± 2.575.5 ± 2.81
Week 164.9 ± 2.933.2 ± 2.753.1 ± 2.632.5 ± 2.453.2 ± 2.423.8 ± 2.693.4 ± 2.773.5 ± 2.915.8 ± 2.76
SecondaryChange From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12

Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch.

Time frame:
Baseline, Week 1, 2, 4, 6, 8, 10 and 12
Reported as:
Least squares mean · Unit on a scale
Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12
Unit on a scaleVehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BID
Change at Week 1-0.4 ± 0.23-0.6 ± 0.23-0.9 ± 0.23-0.9 ± 0.25-0.9 ± 0.22-0.9 ± 0.24-1.0 ± 0.27-1.4 ± 0.28-1.2 ± 0.30
Change at Week 2-0.9 ± 0.28-0.9 ± 0.27-1.1 ± 0.28-1.2 ± 0.30-1.0 ± 0.27-1.3 ± 0.25-1.3 ± 0.29-1.9 ± 0.30-1.5 ± 0.32
Change at Week 4-1.0 ± 0.33-0.8 ± 0.33-1.0 ± 0.34-1.2 ± 0.36-1.2 ± 0.32-1.3 ± 0.32-1.7 ± 0.38-1.7 ± 0.38-1.6 ± 0.41
Change at Week 6-0.9 ± 0.36-0.4 ± 0.36-1.0 ± 0.38-1.2 ± 0.39-1.6 ± 0.36-1.1 ± 0.31-1.9 ± 0.36-1.8 ± 0.36-2.1 ± 0.39
Change at Week 8-1.4 ± 0.38-1.1 ± 0.38-1.2 ± 0.39-1.3 ± 0.41-1.6 ± 0.38-1.2 ± 0.38-2.2 ± 0.44-1.8 ± 0.43-2.2 ± 0.46
Change at Week 10-1.1 ± 0.43-1.4 ± 0.44-1.3 ± 0.45-1.2 ± 0.46-2.1 ± 0.42-0.5 ± 0.39-2.1 ± 0.44-1.9 ± 0.42-1.2 ± 0.47
Change at Week 12-1.0 ± 0.42-1.3 ± 0.43-1.2 ± 0.44-1.3 ± 0.45-1.8 ± 0.42-0.6 ± 0.41-2.3 ± 0.47-1.8 ± 0.44-1.5 ± 0.49
Statistical analysis
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.3232 · Ls mean difference: -0.2 · 90% CI -0.69 to 0.39
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.0736 · Ls mean difference: -0.5 · 90% CI -1.03 to 0.07
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.0743 · Ls mean difference: -0.5 · 90% CI -1.07 to 0.07
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.0641 · Ls mean difference: -0.5 · 90% CI -1.03 to 0.04
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.3887 · Ls mean difference: -0.1 · 90% CI -0.71 to 0.50
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.0767 · Ls mean difference: -0.5 · 90% CI -1.15 to 0.08
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.2529 · Ls mean difference: -0.3 · 90% CI -0.89 to 0.38
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.5304 · Ls mean difference: 0.0 · 90% CI -0.61 to 0.67
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.2920 · Ls mean difference: -0.2 · 90% CI -0.87 to 0.43
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.2593 · Ls mean difference: -0.3 · 90% CI -0.70 to 0.57
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.4310 · Ls mean difference: -0.1 · 90% CI -0.70 to 0.57
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.5477 · Ls mean difference: 0.0 · 90% CI -0.59 to 0.69
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.0696 · Ls mean difference: -0.6 · 90% CI -1.24 to 0.07
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.3583 · Ls mean difference: -0.1 · 90% CI -0.82 to 0.53
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.6826 · Ls mean difference: 0.2 · 90% CI -0.56 to 1.01
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.4570 · Ls mean difference: -0.1 · 90% CI -0.84 to 0.74
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.3265 · Ls mean difference: -0.2 · 90% CI -1.03 to 0.59
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.3039 · Ls mean difference: -0.2 · 90% CI -1.00 to 0.53
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.2086 · Ls mean difference: -0.4 · 90% CI -1.23 to 0.42
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.2172 · Ls mean difference: -0.4 · 90% CI -1.22 to 0.44
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.2855 · Ls mean difference: -0.3 · 90% CI -1.16 to 0.57
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.8372 · Ls mean difference: 0.5 · 90% CI -0.34 to 1.36
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.4792 · Ls mean difference: 0.0 · 90% CI -0.89 to 0.84
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.3331 · Ls mean difference: -0.2 · 90% CI -1.12 to 0.65
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.1080 · Ls mean difference: -0.6 · 90% CI -1.47 to 0.21
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.0455 · Ls mean difference: -0.8 · 90% CI -1.61 to -0.02
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.0761 · Ls mean difference: -0.7 · 90% CI -1.49 to 0.10
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.0273 · Ls mean difference: -1.0 · 90% CI -1.80 to -0.14
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.7214 · Ls mean difference: 0.3 · 90% CI -0.57 to 1.20
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.6132 · Ls mean difference: 0.2 · 90% CI -0.75 to 1.06
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.5704 · Ls mean difference: 0.1 · 90% CI -0.83 to 1.02
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.3449 · Ls mean difference: -0.2 · 90% CI -1.10 to 0.67
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.0493 · Ls mean difference: -1.0 · 90% CI -1.94 to 0.00
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.1490 · Ls mean difference: -0.6 · 90% CI -1.55 to 0.35
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.0540 · Ls mean difference: -1.0 · 90% CI -1.96 to 0.02
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.3119 · Ls mean difference: -0.3 · 90% CI -1.32 to 0.71
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.3947 · Ls mean difference: -0.2 · 90% CI -1.20 to 0.86
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.4205 · Ls mean difference: -0.1 · 90% CI -1.18 to 0.93
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.0472 · Ls mean difference: -1.0 · 90% CI -2.02 to -0.02
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.0044 · Ls mean difference: -1.6 · 90% CI -2.55 to -0.60
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.0098 · Ls mean difference: -1.4 · 90% CI -2.32 to -0.41
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.1285 · Ls mean difference: -0.7 · 90% CI -1.71 to 0.32
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · MMRM · p = 0.3243 · Ls mean difference: -0.3 · 90% CI -1.27 to 0.72
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · MMRM · p = 0.3795 · Ls mean difference: -0.2 · 90% CI -1.20 to 0.82
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · MMRM · p = 0.3070 · Ls mean difference: -0.3 · 90% CI -1.35 to 0.72
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · MMRM · p = 0.1014 · Ls mean difference: -0.8 · 90% CI -1.74 to 0.22
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · MMRM · p = 0.0033 · Ls mean difference: -1.7 · 90% CI -2.75 to -0.69
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · MMRM · p = 0.0280 · Ls mean difference: -1.2 · 90% CI -2.18 to -0.17
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · MMRM · p = 0.0781 · Ls mean difference: -0.9 · 90% CI -1.98 to 0.15
SecondaryChange From Baseline in PP-NRS Score at Week 14 and 16

Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch.

Time frame:
Baseline, Week 14 and 16
Reported as:
Mean · Unit on a scale
Change From Baseline in PP-NRS Score at Week 14 and 16
Unit on a scaleVehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BID
Change at Week 14-0.4 ± 3.18-1.4 ± 1.64-1.8 ± 3.16-1.2 ± 2.52-1.1 ± 2.38-1.0 ± 2.93-1.1 ± 2.57-1.3 ± 2.31-0.1 ± 4.18
Change at Week 16-0.6 ± 2.97-0.9 ± 1.82-1.2 ± 3.21-0.7 ± 2.02-1.0 ± 2.52-0.9 ± 2.99-1.0 ± 2.29-0.9 ± 2.250.4 ± 3.54
SecondaryAbsolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2

PSI was a self-administered 8-item questionnaire that measured the severity of psoriasis symptoms over the past 24 hours and the past 7 days. PSI included following 8 items: itch, pain, burning, stinging, cracking, scaling, flaking, and redness. Each item was rated on a scale from 0 to 4, where 0= not at all severe, 1= mild, 2= moderate, 3= severe and 4= very severe. Scores from all items were summed to give PSI score range from 0 (no severity) to 32 (maximum severity), higher PSI score indicated greater severity.

Time frame:
Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET (Prior to Week 12), ET Follow-up Visit 1 (2 weeks post ET) and 2 (4 weeks post ET)
Reported as:
Mean · Unit on a scale
Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2
Unit on a scaleVehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BID
Baseline14.2 ± 5.9612.3 ± 7.1813.2 ± 6.5510.3 ± 5.0012.3 ± 6.4814.0 ± 6.6013.0 ± 6.0910.1 ± 5.7016.6 ± 7.01
Week 111.2 ± 4.179.1 ± 5.859.7 ± 5.297.8 ± 4.238.9 ± 6.109.6 ± 4.869.5 ± 4.867.0 ± 4.969.7 ± 4.24
Week 210.3 ± 4.578.4 ± 5.079.2 ± 5.037.1 ± 4.018.2 ± 5.178.4 ± 4.529.1 ± 5.476.0 ± 4.308.4 ± 3.62
Week 411.6 ± 5.819.2 ± 5.259.9 ± 5.297.3 ± 3.978.1 ± 4.899.6 ± 6.967.9 ± 5.576.6 ± 4.608.3 ± 3.99
Week 611.6 ± 6.619.7 ± 5.7910.4 ± 6.206.2 ± 3.797.6 ± 4.698.8 ± 5.966.1 ± 3.236.9 ± 5.068.2 ± 4.23
Week 811.3 ± 5.828.7 ± 5.879.7 ± 6.626.1 ± 3.737.0 ± 4.618.4 ± 5.467.2 ± 4.757.5 ± 4.928.0 ± 4.68
Week 1011.7 ± 7.098.0 ± 6.299.5 ± 5.896.5 ± 3.666.4 ± 4.877.8 ± 4.926.7 ± 3.136.7 ± 4.609.5 ± 4.97
Week 1211.7 ± 7.407.8 ± 6.419.7 ± 6.455.9 ± 3.386.2 ± 4.698.0 ± 5.136.1 ± 3.676.8 ± 5.148.3 ± 4.79
Week 1414.3 ± 8.098.1 ± 6.378.9 ± 6.096.8 ± 5.009.2 ± 6.1210.4 ± 5.9811.2 ± 7.548.5 ± 6.0411.5 ± 5.26
Week 1614.0 ± 7.608.6 ± 6.309.8 ± 5.477.4 ± 5.038.9 ± 6.7710.4 ± 6.1811.5 ± 7.2010.2 ± 6.8211.9 ± 7.33
ET7.7 ± 4.0413.0 ± 1.0012.8 ± 6.7613.3 ± 7.0215.8 ± 11.7318.7 ± 10.2318.0 ± 11.8711.0 ± 8.2119.3 ± 8.14
ET follow-up visit 17.0 ± 4.249.0 ± NA6.0 ± 4.244.0 ± NA2.0 ± NA19.0 ± 15.568.5 ± 2.124.0 ± NA7.0 ± NA
ET follow-up visit 28.0 ± 5.667.0 ± NA4.5 ± 2.124.0 ± NA22.5 ± 9.1917.8 ± 11.414.0 ± 0.0013.0 ± 13.7415.5 ± 10.61
SecondaryChange From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2

PSI was a self-administered 8-item questionnaire that measured the severity of psoriasis symptoms over the past 24 hours and the past 7 days. PSI included following 8 items: itch, pain, burning, stinging, cracking, scaling, flaking, and redness. Each item was rated on a scale from 0 to 4, where 0= not at all severe, 1= mild, 2= moderate, 3= severe and 4= very severe. Scores from all items were summed to give PSI score range from 0 (no severity) to 32 (maximum severity), higher PSI score indicated greater severity.

Time frame:
Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET (Prior to Week 12), ET Follow-up Visit 1 (2 weeks post ET) and 2 (4 weeks post ET)
Reported as:
Mean · Unit on a scale
Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2
Unit on a scaleVehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BID
Change at Week 1-3.3 ± 4.94-2.8 ± 3.35-3.0 ± 3.84-2.6 ± 2.95-3.4 ± 4.17-3.9 ± 5.00-3.7 ± 3.49-3.4 ± 3.18-6.6 ± 4.80
Change at Week 2-4.0 ± 5.46-3.9 ± 4.91-4.1 ± 4.36-3.1 ± 3.63-3.8 ± 4.62-5.1 ± 5.85-4.2 ± 3.91-4.3 ± 4.12-7.8 ± 5.37
Change at Week 4-3.0 ± 6.33-3.4 ± 5.09-3.5 ± 5.12-2.6 ± 3.91-4.1 ± 4.55-3.9 ± 6.50-4.6 ± 5.44-3.7 ± 4.57-6.5 ± 5.44
Change at Week 6-3.5 ± 7.09-3.1 ± 5.30-2.0 ± 6.20-3.5 ± 5.22-4.0 ± 4.64-5.1 ± 7.40-6.3 ± 5.05-3.4 ± 4.60-6.5 ± 5.75
Change at Week 8-4.1 ± 7.20-3.5 ± 4.60-3.2 ± 6.56-3.7 ± 5.01-4.1 ± 5.01-5.2 ± 8.12-5.8 ± 5.35-3.2 ± 4.90-7.0 ± 6.64
Change at Week 10-4.0 ± 7.57-4.0 ± 4.90-3.4 ± 6.24-3.3 ± 6.12-5.3 ± 5.69-5.5 ± 8.08-5.1 ± 5.12-3.9 ± 4.82-5.8 ± 7.62
Change at Week 12-3.8 ± 7.74-4.1 ± 4.98-3.2 ± 5.63-3.7 ± 6.13-5.2 ± 6.04-5.0 ± 8.15-5.2 ± 4.82-3.7 ± 5.67-6.6 ± 7.82
Change at Week 14-0.7 ± 7.86-2.9 ± 4.68-4.4 ± 7.49-3.1 ± 6.87-2.2 ± 5.49-3.5 ± 7.87-1.4 ± 5.53-2.3 ± 4.98-2.9 ± 7.98
Change at Week 16-0.9 ± 7.61-2.4 ± 5.02-3.2 ± 6.37-2.4 ± 7.27-2.1 ± 6.05-2.6 ± 7.12-0.8 ± 4.29-0.8 ± 5.28-2.7 ± 8.40
Change at ET-2.7 ± 2.520.7 ± 6.11-1.0 ± 8.290.3 ± 2.08-1.3 ± 6.850.7 ± 5.161.8 ± 7.40-4.0 ± 3.00-5.0 ± 1.41
Change at ET Follow-up Visit 1-2.5 ± 0.71-9.0 ± NA-5.0 ± 7.07-4.0 ± NA-3.0 ± NA2.0 ± 9.90-2.5 ± 0.71-7.0 ± NA-9.0 ± NA
Change at ET Follow-up Visit 2-1.5 ± 2.12-11.0 ± NA-6.5 ± 4.95-4.0 ± NA6.5 ± 9.190.8 ± 7.14-11.0 ± 4.24-0.3 ± 8.26-1.0 ± 9.90
SecondaryPercentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16

PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category. Scale for PGA: 0= clear, 1= almost clear, 2= mild, 3= moderate and 4= severe. Higher scores indicate more severity.

Time frame:
Baseline, Week 1, 2, 4, 6, 8, 10, 14, and 16
Reported as:
Number · Percentage of participants
Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16
Percentage of participantsVehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BID
Week 12.8 (0.3 to 11.6)2.7 (0.3 to 11.2)2.7 (0.3 to 11.2)0 (0.0 to 7.5)0 (0.0 to 7.3)0 (0.0 to 5.5)0 (0.0 to 7.5)5.7 (1.5 to 16.4)5.3 (1.4 to 15.0)
Week 22.8 (0.3 to 11.6)0 (0.0 to 7.3)0 (0.0 to 7.3)2.8 (0.3 to 11.6)2.7 (0.3 to 11.2)2.0 (0.2 to 8.4)0 (0.0 to 7.5)5.7 (1.5 to 16.4)10.5 (4.7 to 21.6)
Week 45.6 (1.5 to 15.9)5.4 (1.4 to 15.5)0 (0.0 to 7.3)5.6 (1.5 to 15.9)5.4 (1.4 to 15.5)8.2 (3.6 to 16.5)8.3 (3.1 to 18.9)11.4 (5.1 to 23.6)21.1 (10.9 to 33.3)
Week 68.3 (3.1 to 18.9)5.4 (1.4 to 15.5)2.7 (0.3 to 11.2)8.3 (3.1 to 18.9)13.5 (6.7 to 24.8)8.2 (3.6 to 16.5)8.3 (3.1 to 18.9)5.7 (1.5 to 16.4)13.2 (6.5 to 24.3)
Week 811.1 (4.9 to 22.9)5.4 (1.4 to 15.5)5.4 (1.4 to 15.5)2.8 (0.3 to 11.6)10.8 (4.8 to 22.2)6.1 (2.3 to 14.8)13.9 (6.9 to 25.4)5.7 (1.5 to 16.4)18.4 (10.1 to 30.9)
Week 108.3 (3.1 to 18.9)5.4 (1.4 to 15.5)8.1 (3.0 to 18.5)8.3 (3.1 to 18.9)16.2 (7.3 to 29.3)16.3 (8.4 to 27.1)16.7 (7.5 to 30.2)8.6 (3.2 to 19.3)13.2 (6.5 to 24.3)
Week 142.8 (0.3 to 11.6)13.5 (6.7 to 24.8)5.6 (1.5 to 15.9)8.6 (3.2 to 19.3)13.5 (6.7 to 24.8)6.3 (2.3 to 15.1)8.8 (3.3 to 19.7)11.8 (5.2 to 24.3)8.1 (3.0 to 18.5)
Week 165.6 (1.5 to 15.9)11.4 (5.1 to 23.6)8.6 (3.2 to 19.3)14.3 (7.1 to 26.0)16.2 (7.3 to 29.3)8.2 (3.6 to 16.5)14.7 (7.3 to 26.9)11.8 (5.2 to 24.3)16.2 (7.3 to 29.3)
Statistical analysis
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.4216 · Risk difference (rd): -0.1 · 90% CI -9.4 to 9.1
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.4216 · Risk difference (rd): -0.1 · 90% CI -9.4 to 9.1
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.7362 · Risk difference (rd): -2.8 · 90% CI -12.5 to 5.0
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.7417 · Risk difference (rd): -2.8 · 90% CI -12.5 to 4.7
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.5000 · Risk difference (rd): 0.0 · 90% CI -5.9 to 8.0
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.0714 · Risk difference (rd): 5.7 · 90% CI -0.8 to 16.9
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.0813 · Risk difference (rd): 5.3 · 90% CI -1.1 to 15.7
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.7417 · Risk difference (rd): -2.8 · 90% CI -12.5 to 4.7
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.7417 · Risk difference (rd): -2.8 · 90% CI -12.5 to 4.7
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.5000 · Risk difference (rd): 0.0 · 90% CI -9.6 to 9.6
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.4216 · Risk difference (rd): -0.1 · 90% CI -9.4 to 9.1
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.6894 · Risk difference (rd): -2.0 · 90% CI -9.4 to 5.9
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.2518 · Risk difference (rd): 3.7 · 90% CI -4.2 to 14.3
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.0565 · Risk difference (rd): 8.5 · 90% CI -0.3 to 20.3
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.4446 · Risk difference (rd): -0.2 · 90% CI -11.0 to 11.0
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.9001 · Risk difference (rd): -5.6 · 90% CI -16.5 to 1.9
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.5000 · Risk difference (rd): 0.0 · 90% CI -11.0 to 11.0
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.4446 · Risk difference (rd): -0.2 · 90% CI -11.0 to 11.0
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.5054 · Risk difference (rd): 0.2 · 90% CI -10.5 to 12.5
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.3401 · Risk difference (rd): 3.3 · 90% CI -8.2 to 16.9
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.0489 · Risk difference (rd): 12.9 · 90% CI 0.1 to 27.5
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.6349 · Risk difference (rd): -2.9 · 90% CI -14.8 to 8.4
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.8253 · Risk difference (rd): -5.6 · 90% CI -17.2 to 4.4
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.5000 · Risk difference (rd): 0.0 · 90% CI -12.5 to 12.5
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.2709 · Risk difference (rd): 5.2 · 90% CI -8.3 to 19.1
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.5054 · Risk difference (rd): 0.2 · 90% CI -10.5 to 12.5
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.6319 · Risk difference (rd): -2.4 · 90% CI -12.9 to 9.3
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.3199 · Risk difference (rd): 5.0 · 90% CI -6.4 to 18.1
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.7306 · Risk difference (rd): -5.7 · 90% CI -19.1 to 6.1
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.7306 · Risk difference (rd): -5.7 · 90% CI -19.1 to 6.1
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.8808 · Risk difference (rd): -8.3 · 90% CI -20.6 to 2.7
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.4644 · Risk difference (rd): -0.3 · 90% CI -13.7 to 13.7
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.1534 · Risk difference (rd): 7.8 · 90% CI -3.4 to 20.9
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.4867 · Risk difference (rd): -0.4 · 90% CI -10.0 to 11.4
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.0435 · Risk difference (rd): 12.3 · 90% CI 0.4 to 25.9
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.6349 · Risk difference (rd): -2.9 · 90% CI -14.8 to 8.4
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.4565 · Risk difference (rd): -0.2 · 90% CI -12.6 to 12.5
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.5000 · Risk difference (rd): 0.0 · 90% CI -12.5 to 12.5
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.1765 · Risk difference (rd): 7.9 · 90% CI -5.7 to 21.8
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.5013 · Risk difference (rd): 0.3 · 90% CI -14.0 to 15.2
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.7969 · Risk difference (rd): -7.8 · 90% CI -20.7 to 5.9
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.6424 · Risk difference (rd): -3.2 · 90% CI -16.4 to 10.6
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.0620 · Risk difference (rd): 10.7 · 90% CI -0.7 to 23.6
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.3402 · Risk difference (rd): 2.8 · 90% CI -7.0 to 13.4
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.1743 · Risk difference (rd): 5.8 · 90% CI -4.5 to 17.6
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.0620 · Risk difference (rd): 10.7 · 90% CI -0.7 to 23.6
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.3534 · Risk difference (rd): 2.6 · 90% CI -7.8 to 15.4
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.2508 · Risk difference (rd): 5.5 · 90% CI -5.5 to 18.8
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.4238 · Risk difference (rd): 1.9 · 90% CI -8.2 to 13.6
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.2696 · Risk difference (rd): 5.9 · 90% CI -6.2 to 19.3
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.3648 · Risk difference (rd): 3.0 · 90% CI -8.6 to 15.3
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.1267 · Risk difference (rd): 8.7 · 90% CI -3.8 to 22.2
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.0832 · Risk difference (rd): 10.7 · 90% CI -2.5 to 24.4
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.2099 · Risk difference (rd): 6.5 · 90% CI -5.7 to 21.3
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.3474 · Risk difference (rd): 3.6 · 90% CI -8.0 to 17.4
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.2124 · Risk difference (rd): 8.1 · 90% CI -4.0 to 21.6
SecondaryPercentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16

PSI was a self-administered 8-item questionnaire that measured the severity of psoriasis symptoms over the past 24 hours and the past 7 days. PSI included following 8 items: itch, pain, burning, stinging, cracking, scaling, flaking, and redness. Each item was rated on a scale from 0 to 4, where 0= not at all severe, 1= mild, 2= moderate, 3= severe and 4= very severe. Scores from all items were summed to give PSI score range from 0 (no severity) to 32 (maximum severity), higher PSI score indicated greater severity.

Time frame:
Week 1, 2, 4, 6, 8, 10, 12, 14, and 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16
Percentage of participantsVehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BID
Week 15.7 (1.5 to 16.4)19.4 (10.7 to 32.8)11.8 (5.2 to 24.3)22.2 (11.6 to 35.3)13.5 (6.7 to 24.8)19.1 (11.2 to 30.3)11.4 (5.1 to 23.6)26.5 (15.9 to 40.5)24.1 (13.4 to 38.5)
Week 28.6 (3.2 to 19.3)22.2 (11.6 to 35.3)18.2 (8.2 to 31.3)34.3 (22.0 to 47.8)31.4 (19.3 to 44.8)20.8 (11.8 to 31.5)25.7 (15.4 to 39.2)31.4 (19.3 to 44.8)32.3 (18.7 to 48.2)
Week 415.6 (7.8 to 28.7)29.0 (17.6 to 45.0)29.6 (15.7 to 45.3)48.5 (34.4 to 63.9)38.2 (24.3 to 53.8)26.1 (15.8 to 37.7)31.0 (18.9 to 46.3)51.6 (36.8 to 67.3)35.5 (21.3 to 51.8)
Week 618.8 (8.5 to 32.0)26.7 (14.0 to 41.6)32.0 (17.0 to 50.0)54.8 (39.9 to 70.3)42.9 (28.4 to 60.0)31.6 (19.9 to 45.9)66.7 (50.0 to 79.6)48.1 (32.6 to 65.3)33.3 (20.4 to 50.0)
Week 823.3 (12.9 to 37.6)35.5 (21.3 to 51.8)46.2 (29.9 to 63.8)67.7 (51.8 to 81.3)50.0 (34.2 to 65.8)41.7 (29.0 to 56.0)62.5 (44.7 to 77.9)35.7 (20.8 to 52.7)59.3 (41.7 to 75.2)
Week 1031.0 (18.9 to 46.3)42.9 (28.4 to 60.0)40.0 (24.6 to 58.3)62.1 (46.3 to 77.1)64.3 (47.3 to 79.2)45.2 (29.7 to 60.1)50.0 (31.9 to 68.1)46.4 (31.0 to 63.4)33.3 (17.8 to 52.1)
Week 1224.1 (13.4 to 38.5)51.7 (35.2 to 68.0)50.0 (34.2 to 65.8)62.1 (46.3 to 77.1)55.6 (38.2 to 70.9)35.5 (21.3 to 51.8)56.5 (38.1 to 72.7)46.4 (31.0 to 63.4)36.0 (21.4 to 54.4)
Week 147.1 (1.9 to 20.1)44.0 (27.0 to 61.1)45.8 (28.2 to 63.0)54.2 (37.0 to 71.8)37.0 (22.1 to 54.7)25.9 (14.5 to 41.7)30.4 (17.3 to 47.9)36.0 (21.4 to 54.4)17.4 (7.8 to 33.5)
Week 167.4 (2.0 to 20.4)44.4 (29.1 to 61.8)30.4 (17.3 to 47.9)54.2 (37.0 to 71.8)52.0 (36.0 to 69.3)36.7 (22.1 to 52.4)18.2 (8.2 to 35.3)22.7 (11.5 to 39.5)31.6 (15.1 to 53.0)
Statistical analysis
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.0544 · Risk difference (rd): 13.7 · 90% CI -0.3 to 27.9
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.2697 · Risk difference (rd): 6.1 · 90% CI -6.3 to 19.6
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.0286 · Risk difference (rd): 16.5 · 90% CI 2.0 to 31.0
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.1512 · Risk difference (rd): 7.8 · 90% CI -4.7 to 20.8
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.7900 · Risk difference (rd): -7.7 · 90% CI -21.9 to 7.4
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.3137 · Risk difference (rd): 7.3 · 90% CI -8.5 to 24.0
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.3789 · Risk difference (rd): 5.0 · 90% CI -10.9 to 22.6
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.0636 · Risk difference (rd): 13.7 · 90% CI -1.0 to 28.5
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.1435 · Risk difference (rd): 9.6 · 90% CI -4.9 to 24.5
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.0058 · Risk difference (rd): 25.7 · 90% CI 8.9 to 42.4
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.0112 · Risk difference (rd): 22.9 · 90% CI 6.5 to 38.9
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.3349 · Risk difference (rd): 4.9 · 90% CI -10.8 to 21.3
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.2065 · Risk difference (rd): 10.6 · 90% CI -6.1 to 27.7
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.1871 · Risk difference (rd): 11.4 · 90% CI -5.6 to 29.1
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.1245 · Risk difference (rd): 13.4 · 90% CI -4.9 to 31.4
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.1280 · Risk difference (rd): 14.0 · 90% CI -4.7 to 33.7
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.0030 · Risk difference (rd): 32.9 · 90% CI 12.4 to 50.5
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.0235 · Risk difference (rd): 22.6 · 90% CI 3.1 to 40.6
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.3728 · Risk difference (rd): 4.9 · 90% CI -13.6 to 24.1
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.0153 · Risk difference (rd): 25.5 · 90% CI 4.0 to 43.6
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.2543 · Risk difference (rd): 9.4 · 90% CI -8.8 to 27.8
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.2785 · Risk difference (rd): 7.9 · 90% CI -10.2 to 26.4
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.1434 · Risk difference (rd): 13.3 · 90% CI -7.4 to 33.7
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.0015 · Risk difference (rd): 36.1 · 90% CI 12.8 to 54.1
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.0242 · Risk difference (rd): 24.1 · 90% CI 3.4 to 43.9
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.0037 · Risk difference (rd): 35.1 · 90% CI 10.0 to 54.1
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.1037 · Risk difference (rd): 16.6 · 90% CI -4.9 to 36.7
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.4607 · Risk difference (rd): 1.8 · 90% CI -17.7 to 22.5
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.1725 · Risk difference (rd): 12.2 · 90% CI -8.0 to 31.9
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.0451 · Risk difference (rd): 22.8 · 90% CI 0.2 to 43.6
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.0003 · Risk difference (rd): 44.4 · 90% CI 21.3 to 62.9
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.0239 · Risk difference (rd): 26.7 · 90% CI 3.8 to 47.6
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.0643 · Risk difference (rd): 20.8 · 90% CI -2.1 to 41.2
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.6676 · Risk difference (rd): -6.0 · 90% CI -25.9 to 15.9
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.0898 · Risk difference (rd): 17.6 · 90% CI -4.2 to 37.8
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.2707 · Risk difference (rd): 11.8 · 90% CI -10.1 to 32.9
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.2981 · Risk difference (rd): 9.0 · 90% CI -14.2 to 31.0
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.0110 · Risk difference (rd): 31.0 · 90% CI 8.0 to 51.4
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.0083 · Risk difference (rd): 33.3 · 90% CI 9.1 to 53.2
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.4217 · Risk difference (rd): 4.8 · 90% CI -18.3 to 27.5
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.5152 · Risk difference (rd): 1.3 · 90% CI -20.8 to 23.2
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.7002 · Risk difference (rd): -11.8 · 90% CI -33.1 to 11.7
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.0169 · Risk difference (rd): 27.6 · 90% CI 5.2 to 47.9
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.0283 · Risk difference (rd): 25.9 · 90% CI 3.2 to 46.2
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.0020 · Risk difference (rd): 37.9 · 90% CI 14.3 to 57.1
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.0095 · Risk difference (rd): 31.4 · 90% CI 8.4 to 51.5
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.0798 · Risk difference (rd): 21.0 · 90% CI -2.7 to 42.6
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.2848 · Risk difference (rd): 10.9 · 90% CI -11.3 to 31.8
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.5062 · Risk difference (rd): 0.5 · 90% CI -21.1 to 23.1
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.0012 · Risk difference (rd): 36.9 · 90% CI 16.7 to 55.3
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.0007 · Risk difference (rd): 38.7 · 90% CI 17.3 to 57.4
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.0001 · Risk difference (rd): 47.0 · 90% CI 24.6 to 65.1
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.0039 · Risk difference (rd): 29.9 · 90% CI 9.5 to 48.7
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.3895 · Risk difference (rd): 4.5 · 90% CI -17.5 to 26.5
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.2793 · Risk difference (rd): 10.1 · 90% CI -11.8 to 31.8
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.7027 · Risk difference (rd): -8.5 · 90% CI -28.4 to 12.2
  • Vehicle Once Daily (QD) vs PF-06700841 0.1% QD · Chan and Zhang method · p = 0.0009 · Risk difference (rd): 37.0 · 90% CI 15.4 to 55.2
  • Vehicle Once Daily (QD) vs PF-06700841 0.3% QD · Chan and Zhang method · p = 0.0205 · Risk difference (rd): 23.0 · 90% CI 4.1 to 43.2
  • Vehicle Once Daily (QD) vs PF-06700841 1.0% QD · Chan and Zhang method · p = 0.0001 · Risk difference (rd): 46.8 · 90% CI 24.6 to 65.7
  • Vehicle Once Daily (QD) vs PF-06700841 3.0% QD · Chan and Zhang method · p = 0.0002 · Risk difference (rd): 44.6 · 90% CI 21.5 to 62.9
  • Pooled Vehicle BID vs PF-06700841 0.3% BID · Chan and Zhang method · p = 0.9209 · Risk difference (rd): -18.5 · 90% CI -38.3 to 3.2
  • Pooled Vehicle BID vs PF-06700841 1.0% BID · Chan and Zhang method · p = 0.7930 · Risk difference (rd): -13.9 · 90% CI -34.4 to 8.7
  • Pooled Vehicle BID vs PF-06700841 3.0% BID · Chan and Zhang method · p = 0.6156 · Risk difference (rd): -5.1 · 90% CI -28.0 to 20.1
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and all non-SAEs. Treatment emergent AEs (TEAEs) were events that occurred between first dose of study drug and up to 4 weeks after last dose that were absent before treatment or that worsened relative to pretreatment state. A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug. Relatedness to study drug was assessed by the investigator.

Time frame:
Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs
ParticipantsVehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BID
Treatment-emergent AEs171614171420131812
Treatment-emergent SAEs100101120
Treatment-related AEs102232331
Treatment-related SAEs000000000
SecondaryNumber of Participants With TEAEs by Severity

An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. AE was assessed according to severity; mild (not causing any significant problem, dose adjustment not required), moderate (caused problem that does not interfere significantly with usual activities or the clinical status, dose adjustment needed due to adverse event) and severe (caused problem that interfered significantly with usual activities or the clinical status, study drug stopped due to adverse event).

Time frame:
Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs by Severity
ParticipantsVehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BID
Mild1291111787116
Moderate5735711656
Severe000101020
SecondaryNumber of Participants Who Discontinued From Study Due to Adverse Events

An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.

Time frame:
Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks)
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued From Study Due to Adverse Events
ParticipantsVehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BID
Number of Participants Who Discontinued From Study Due to Adverse Events113021121
SecondaryNumber of Participants With Laboratory Abnormalities Meeting Specified Criteria

Bilirubin: greater than (\>) 1.5\* upper limit normal (ULN); aspartate aminotransferase, alanine aminotransferase: \>2.5\*ULN; creatinine, cystatin C: \>1.3\*ULN; creatine kinase: \>2.0\*ULN; glomerular filtration rate (GFR) CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) Equat: less than (\<) 60 milliliter (mL)/minute (min)/1.73 meter(m)\^2, greater than or equal to (\>=) 30% decrease from baseline; GFR: \<60 mL/min/1.73m\^2.

Time frame:
Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities Meeting Specified Criteria
ParticipantsVehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BID
Number of Participants With Laboratory Abnormalities Meeting Specified Criteria761175125615
SecondaryNumber of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data

Following were ECG criteria used for categorical summary:1) PR interval: percentage change \>=25/50%, QRS interval: value \>140 msec, and QT interval corrected using the Fridericia's formula (QTcF): 450 msec \< value less than equal to (\<=) 480 and 30 \< change \<=60.

Time frame:
Post-baseline to Week 6, Post-baseline to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data
ParticipantsVehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BID
Post-baseline to Week 6: PR interval (>=25/50 percent)000101000
Post-baseline to Week 6: QRS interval (>=140 msec)010001000
Post-baseline to Week 6: QTcF interval (30< Change <=60)100110002
Post-baseline to Week 12: PR interval (>=25/50 percent)000111000
Post-baseline to Week 12: QRS interval (>=140 msec)010002010
Post-baseline to Week 12: QTcF interval (450< Value <=480)000002111
Post-baseline to Week 12: QTcF interval (30 < Chg <= 60)200002001
SecondaryNumber of Participants With Categorical Summary of Post-Baseline Vital Signs Data

Following were the vital signs criteria: 1) Pulse rate: value \<40 beats per min (bpm), value \>120 bpm; 2) Sitting diastolic blood pressure (DBP): value \<50 mmHg; change \>=20 mmHg increase; change \>=20 mmHg decrease; 3) Sitting systolic blood pressure (SBP): value \<90 mmHg, change \>=30 mmHg increase, change \>=30 mmHg decrease; 4) Supine DBP: value \<50 mmHg, change \>=20 mmHg increase, change \>=20 mmHg decrease; 5) Supine SBP: value \<90 mmHg, change \>=30 mmHg increase, change \>=30 mmHg decrease.

Time frame:
Post-baseline to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data
ParticipantsVehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BID
Pulse rate < 40 bpm000000000
Pulse rate >120 bpm000000000
Sitting DBP (<50 mmHg)000000000
Sitting DBP (>=20 mmHg increase)000000000
Sitting DBP (>=20 mmHg decrease)000000000
Sitting SBP (<90 mmHg)000000000
Sitting SBP (>= 30 mmHg increase)000000001
Sitting SBP (>=30 mmHg decrease)000000010
Supine DBP (<50 mmHg)000000000
Supine DBP (>= 20mmHg increase)011100022
Supine DBP (>=20 mmHg decrease)020014000
Supine SBP (<90 mmHg)100000000
Supine SBP (>=30 mmHg increase)101202021
Supine SBP (>= 30 mmHg decrease)101100111
SecondaryNumber of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16

At the site of study drug application, skin tolerability was assessed for non-lesional skin surrounding the plaques on a scale from 0 to 4. Grade 0= none (no evidence of local intolerance), Grade 1= mild (minimal erythema and/or edema, slight glazed appearance), Grade 2= moderate (definite erythema and/or oedema with peeling and/or cracking but needs no adaptation of posology), Grade 3= severe, reported as AE (erythema, oedema glazing with fissures, few vesicles or papules: consider removing topical agent \[if still in place\]), Grade 4= very severe, reported as AE (strong reaction spreading beyond the treated area, bullous reaction, erosions: removal of topical agent \[if still in place\]).

Time frame:
Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16
Reported as:
Count of participants · Participants
Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16
ParticipantsVehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BID
Day1 — None363736363648353637
Day1 — Mild101010001
Day1 — Moderate000000100
Day1 — Severe000000000
Day1 — Very severe000000000
Day1 — Missing000001000
Week 1 — None323532343544323235
Week 1 — Mild101201021
Week 1 — Moderate000000000
Week 1 — Severe000000000
Week 1 — Very severe000000000
Week 1 — Missing314024421
Week 2 — None333530343545343533
Week 2 — Mild101101002
Week 2 — Moderate000000100
Week 2 — Severe000000000
Week 2 — Very severe000000000
Week 2 — Missing115112012
Week 4 — None343229323444303230
Week 4 — Mild000201003
Week 4 — Moderate000000000
Week 4 — Severe000000000
Week 4 — Very severe000000000
Week 4 — Missing025112232
Week 6 — None323126302737283130
Week 6 — Mild001110000
Week 6 — Moderate000000000
Week 6 — Severe000000000
Week 6 — Very severe000000000
Week 6 — Missing115437342
Week 8 — None293027302634263028
Week 8 — Mild000011000
Week 8 — Moderate100100000
Week 8 — Severe000000000
Week 8 — Very severe000000000
Week 8 — Missing226446344
Week 10 — None293024292734242726
Week 10 — Mild001110000
Week 10 — Moderate000000000
Week 10 — Severe000000000
Week 10 — Very severe000000000
Week 10 — Missing317336474
Week 12 — None333230313043303229
Week 12 — Mild000110000
Week 12 — Moderate000000111
Week 12 — Severe000000000
Week 12 — Very severe000000000
Week 12 — Missing346343335
Week 14 — None312724293034262628
Week 14 — Mild000000000
Week 14 — Moderate000000000
Week 14 — Severe000000000
Week 14 — Very severe000000000
Week 14 — Missing57105411895
Week 16 — None312826282835262826
Week 16 — Mild000000010
Week 16 — Moderate000000000
Week 16 — Severe000000000
Week 16 — Very severe000000000
Week 16 — Missing4797410867

Adverse events

Collected over Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vehicle Once Daily (QD)0/37 (0%)1/37 (2.7%)7/37 (18.9%)
PF-06700841 0.1% QD0/37 (0%)0/37 (0%)7/37 (18.9%)
PF-06700841 0.3% QD0/37 (0%)0/37 (0%)7/37 (18.9%)
PF-06700841 1.0% QD0/36 (0%)1/36 (2.8%)9/36 (25%)
PF-06700841 3.0% QD0/37 (0%)0/37 (0%)8/37 (21.6%)
Pooled Vehicle BID1/49 (2%)1/49 (2%)10/49 (20.4%)
PF-06700841 0.3% BID0/36 (0%)1/36 (2.8%)4/36 (11.1%)
PF-06700841 1.0% BID0/36 (0%)2/36 (5.6%)10/36 (27.8%)
PF-06700841 3.0% BID0/38 (0%)0/38 (0%)2/38 (5.3%)
Most frequent serious events
Most frequent serious events
EventVehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BID
Thrombophlebitis septicInfections and infestations0/370/370/370/360/370/490/361/360/38
Urinary tract infectionInfections and infestations0/370/370/370/360/370/490/361/360/38
Aspiration bursaInvestigations0/370/370/371/360/370/490/360/360/38
LethargyNervous system disorders0/370/370/370/360/370/490/361/360/38
DepressionPsychiatric disorders0/370/370/370/360/370/491/360/360/38
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/370/370/370/360/370/490/361/360/38
BacteraemiaInfections and infestations1/370/370/370/360/370/490/360/360/38
Cardiopulmonary failureCardiac disorders0/370/370/370/360/371/490/360/360/38
Most frequent other events
Most frequent other events
EventVehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BID
NasopharyngitisInfections and infestations4/373/371/376/363/373/491/367/360/38
Blood creatine phosphokinase increasedInvestigations1/370/370/372/361/370/490/360/360/38
CoughRespiratory, thoracic and mediastinal disorders1/370/372/371/360/372/492/362/360/38
PruritusSkin and subcutaneous tissue disorders1/370/371/370/360/371/490/362/361/38
HypertensionVascular disorders0/370/371/370/362/372/490/362/361/38
RhinitisInfections and infestations0/371/372/370/360/371/490/360/360/38
Upper respiratory tract infectionInfections and infestations1/372/371/370/362/372/491/360/361/38
HeadacheNervous system disorders0/372/370/370/360/370/491/360/360/38

Baseline characteristics

Analysis population included participants who were randomly assigned to PF-06700841 and applied at least 1 dose of PF-06700841.

Age, Continuous
Age, Continuous(Years)Vehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BIDTotal
Mean48.6 ± 15.8351.8 ± 12.4951.4 ± 12.2649.4 ± 15.3048.4 ± 12.3750.9 ± 12.8548.2 ± 13.5850.9 ± 16.4548.9 ± 12.9349.9 ± 13.72
Sex: Female, Male
Sex: Female, Male(Participants)Vehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BIDTotal
Female1210761318111114102
Male252730302431252524241
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Vehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BIDTotal
Hispanic or Latino52412833735
Not Hispanic or Latino323533353539333331306
Unknown or Not Reported0000020002
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Vehicle Once Daily (QD)PF-06700841 0.1% QDPF-06700841 0.3% QDPF-06700841 1.0% QDPF-06700841 3.0% QDPooled Vehicle BIDPF-06700841 0.3% BIDPF-06700841 1.0% BIDPF-06700841 3.0% BIDTotal
American Indian or Alaska Native0010100002
Asian64664363240
Native Hawaiian or Other Pacific Islander0000000000
Black or African American1020010127
White303328303245303134293
More than one race0000000101
Unknown or Not Reported0000000000
08

Study locations

79 sites
  • Center for Dermatology and Plastic Surgery/CCT
    Scottsdale, Arizona 85260, United States
  • Center for Dermatology and Plastic Surgery
    Scottsdale, Arizona 85260, United States
  • Burke Pharmaceutical Research
    Hot Springs, Arkansas 71913, United States
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • California Skin Institute
    Anaheim, California 92801, United States
  • California Dermatology & Clinical Research Institute
    Encinitas, California 92024, United States
  • First OC Dermatology
    Fountain Valley, California 92708, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • New England Research Associates, LLC
    Bridgeport, Connecticut 06606, United States
  • Dermatology Physicians of Connecticut
    Shelton, Connecticut 06484, United States
  • Olympian Clinical Research
    Clearwater, Florida 33756, United States
  • Accel Research Sites - DeLand Clinical Research Unit
    DeLand, Florida 32720, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • MidState Skin Institute
    Ocala, Florida 34471, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Park Avenue Dermatology, PA
    Orange Park, Florida 32073, United States
  • Center for Clinical Studies
    Tampa, Florida 33613, United States
  • Dundee Dermatology
    West Dundee, Illinois 60118, United States
  • Ds Research
    Clarksville, Indiana 47129, United States
  • DS Research
    Louisville, Kentucky 40241, United States
  • Meridian Clinical Research, LLC
    Baton Rouge, Louisiana 70808, United States
  • MediSearch Clinical Trials
    Saint Joseph, Missouri 64506, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • Psoriasis Treatment Center of Central New Jersey
    East Windsor, New Jersey 08520, United States
  • Bayside Dermatology Center
    Bayside, New York 11360, United States
  • Dermatology Consulting Services, PLLC
    High Point, North Carolina 27262, United States
  • M3 Wake Research, Inc.
    Raleigh, North Carolina 27612, United States
  • Vital Prospects Clinical Research Institute, PC
    Tulsa, Oklahoma 74136, United States
  • Health Concepts
    Rapid City, South Dakota 57702, United States
  • Rivergate Dermatology Clinical Research
    Goodlettsville, Tennessee 37072, United States
  • Austin Institute for Clinical Research, Inc.
    Austin, Texas 78705, United States
  • studies in Dermatology, LLC
    Cypress, Texas 77433, United States
  • Center for Clinical Studies, LTD. LLP
    Houston, Texas 77004, United States
  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
  • Center for Clinical Studies
    Webster, Texas 77598, United States
  • Summit Clinical Research, LLC
    Franklin, Virginia 23851, United States
  • Virginia Dermatology and Skin Cancer Center
    Norfolk, Virginia 23502, United States
  • Veracity Clinical Research Pty Ltd
    Woolloongabba, Queensland 4102, Australia
  • Emeritus Research
    Camberwell, Victoria 3124, Australia
  • Sinclair Dermatology
    East Melbourne, Victoria 3002, Australia
  • Cabrini Hospital
    Malvern, Victoria 3144, Australia
  • Center for Skin and Venereal Diseases EOOD - Sofia
    Sofia, 1404, Bulgaria
  • DCC Alexandrovska
    Sofia, 1431, Bulgaria
  • Diagnostic Consultative Center - Fokus-5 - Medical Establishment for Outpatient Care OOD
    Sofia, 1463, Bulgaria
  • Dermatological Clinic Sofia
    Sofia, 1756, Bulgaria
  • Wiseman Dermatology Research Inc.
    Winnipeg, Manitoba R3M 3Z4, Canada
  • SKiN Health
    Cobourg, Ontario K9A 4J9, Canada
  • Innovaderm Research Inc.
    Montreal, Quebec H2X 2V1, Canada
  • Diex Recherche Sherbrooke Inc.
    Sherbrooke, Quebec J1L 0H8, Canada
  • Gentofte Hospital
    Hellerup, 2900, Denmark
  • Fachklinik Bad Bentheim
    Bad Bentheim, 48455, Germany
  • Emovis GmbH
    Berlin, 10629, Germany
  • Rothhaar Studien GmbH
    Berlin, 10783, Germany
  • ISA - Interdisciplinary Study Association GmbH
    Berlin, 10789, Germany
  • Klinikum Bielefeld gem.GmbH
    Bielefeld, 33647, Germany
  • Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden
    Dresden, 01307, Germany
  • MENSINGDERMA research GmbH
    Hamburg, 22391, Germany
  • MVZ Alstermed GmbH
    Hamburg, 22391, Germany
  • Dermatologische Gemeinschaftspraxis
    Mahlow, 15831, Germany
  • Klinische Forschung Schwerin GmbH
    Schwerin, 19055, Germany
  • Semmelweis Egyetem Altalanos Orvostudomanyi Kar
    Budapest, 1085, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
  • Bacs-Kiskun Megyei Korhaz Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar Oktato Korhaza
    Kecskemet, 6000, Hungary
  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
    Szeged, 6720, Hungary
  • Kitago Dermatology Clinic
    Sapporo-shi, Hokkaido 003-0833, Japan
  • Nakatsuhifuka Clinic
    Kita-ku, Osaka-shi, Osaka 531-0072, Japan
  • Parkside Hiroo Ladies Clinic
    Minato-ku, Tokyo 106-0047, Japan
  • Tanpopo Skin Clinic
    Ota Ku, Tokyo 143-0023, Japan
  • Samoncho Dermatological Clinic
    Shinjuku-ku, Tokyo 160-0017, Japan
  • Medical Corporation Jitai-kai Tachikawa Dermatology Clinic
    Tachikawa, Tokyo 190-0023, Japan
  • Riga 1st Hospital
    Riga, LV-1001, Latvia
  • Aesthetic dermatology clinic of Prof. J. Kisis
    Riga, LV-1003, Latvia
  • Health and Aesthetics Ltd
    Riga, LV-1009, Latvia
  • Outpatient Clinic of Ventspils
    Ventspils, LV3601, Latvia
  • Zdrowie Osteo-Medic s.c. LiA Racewicz, AiJ Supronik
    Bialystok, 15-351, Poland
  • Nasz Lekarz Przychodnie Medyczne
    Torun, 87-100, Poland
  • MTZ Clinical Research Sp. z o.o
    Warszawa, 02-106, Poland
  • WroMedica I. Bielicka, A. Strzalkowska s.c.
    Wroclaw, 51-685, Poland
09

References and documents

Publications

  • Forman SB, Pariser DM, Poulin Y, Vincent MS, Gilbert SA, Kieras EM, Qiu R, Yu D, Papacharalambous J, Tehlirian C, Peeva E. TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial. J Invest Dermatol. 2020 Dec;140(12):2359-2370.e5. doi: 10.1016/j.jid.2020.03.962. Epub 2020 Apr 18. PubMed 32311398 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Apr 2021, 24 months.

Results were first posted in Jun 2022, 1 year 2 months after primary completion.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 24 months is above that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2019
First posted
Feb 21, 2019
StartActual
Apr 8, 2019
Primary completionActual
Apr 20, 2021
CompletionActual
Apr 20, 2021
Results first posted
Jun 29, 2022
Last update
Jun 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03850483
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 21, 2019
Start date
Apr 8, 2019
Primary completion
Apr 20, 2021
Completion
Apr 20, 2021
Results posted
Jun 29, 2022
Last update
Jun 29, 2022

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06700841

Start the discussion